L-glutamine Gut Health Randomized Trial: What the Evidence Says

L-glutamine Gut Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are

3 min read · 515 wordsReviewed May 2026
Close-up of the word 'probiotic' crafted from letter tiles on a wooden surface. - Evidence evidence guide for L-glutamine Gut Health Randomized Trial: What the Evidence Says
Photo by Alicia Harper on Pexels · Pexels License

Quick Answer

L glutamine Gut Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence aware guidance rather than medical advice.

Key Takeaways

  • 01This page is generated only from sources stored in the Migaku evidence knowledge base.
  • 02Current evidence mix: 1 systematic review, 1 narrative review.
  • 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
  • 04This article is educational and does not replace care from a qualified clinician.

L-glutamine Gut Health Randomized Trial: What the Evidence Says

Quick Answer

L-glutamine Gut Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

  • This page is generated only from sources stored in the Migaku evidence knowledge base.
  • Current evidence mix: 1 systematic review, 1 narrative review.
  • Claims should be interpreted with the source type, study design, population, and publication date in mind.
  • This article is educational and does not replace care from a qualified clinician.

Evidence Map

Source Evidence type Level Date Identifier
The effect of immunonutrition on postoperative ileus following colorectal cancer surgery: a systematic review and meta-analysis of randomized controlled trials systematic review 1 2026-04-10 10.3389/fnut.2026.1778464
High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health narrative review 3 2026-02-14 10.3748/wjg.v32.i6.113804

What The Sources Report

  • In the United States alone, the annual healthcare cost associated with postoperative ileus is estimated to exceed 1.4 billion dollars. [Zhang Yuqiang (2026); evidence level 1]
  • High-protein diets have dual effects on metabolic dysfunction-associated steatotic liver disease, depending on protein source and amount. [Yin Hong-Yuan (2026); evidence level 3]
  • Patients with metabolic dysfunction-associated steatotic liver disease should favor plant proteins and limit animal proteins; personalized dietary strategies require further mechanistic research. [Yin Hong-Yuan (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For l-glutamine gut health randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

  • Zhang Yuqiang (2026). The effect of immunonutrition on postoperative ileus following colorectal cancer surgery: a systematic review and meta-analysis of randomized controlled trials. DOI: 10.3389/fnut.2026.1778464. PMCID: PMC13106113. PMID: 42039896. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13106113/
  • Yin Hong-Yuan (2026). High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health. DOI: 10.3748/wjg.v32.i6.113804. PMCID: PMC12898319. PMID: 41695277. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12898319/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.

FAQ

Frequently Asked Questions

M

Medically reviewed

Last reviewed May 22, 2026 by Migaku Evidence Review

← All GuidesSupplement Reference →